What is Tirzepatide?
Tirzepatide is a first-in-class dual GIP and GLP-1 receptor agonist. FDA-approved as Mounjaro (diabetes) and Zepbound (weight management). It offers superior weight loss compared to GLP-1-only agonists by targeting two incretin pathways simultaneously.
Key Benefits & Mechanisms
Superior weight loss (up to 22% body weight)
Dual incretin pathway activation
Excellent glycemic control
Reduced cardiovascular risk markers
Improved insulin sensitivity
Significant HbA1c reduction
Reduced appetite and food intake
Research Summary
Tirzepatide clinical trials (SURMOUNT, SURPASS) show it outperforms semaglutide in head-to-head comparisons for weight loss. The dual agonist mechanism provides additive metabolic benefits.